TEST:

AlphaLiquid HRR ctDNA test

"South Korean liquid biopsy firm IMBdx said Thursday that it is expanding an ongoing collaboration with AstraZeneca under a project called PROSPER 2.0, which aims to improve access to targeted therapies for individuals with metastatic prostate cancer in markets outside the US...As part of the PROSPER 2.0 project, IMBdx and AstraZeneca are exploring ways to increase clinician and patient awareness of the availability and utility of ctDNA testing to guide the use of targeted therapies in advanced prostate cancer, and of the capabilities of the AlphaLiquid HRR ctDNA test in particular."